Related Experiment Video
Updated: Feb 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Exploring the Crosstalk Between LMNA and Splicing Machinery Gene Mutations in Dilated Cardiomyopathy
Hind C Zahr1, Diana E Jaalouk1
1Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon.
Insights
Mutations in the LMNA gene cause laminopathies like Dilated Cardiomyopathy (DCM). This review explores LMNA mutations, splicing alterations, and their interaction in DCM pathogenesis.
Area of Science:
- Genetics
- Molecular Biology
- Cardiology
Background:
- Laminopathies, including Dilated Cardiomyopathy (DCM), arise from mutations in the LMNA gene, encoding nuclear lamina proteins.
- LMNA mutations are a significant cause of DCM, a progressive heart muscle disease.
- Over 60 genes are linked to DCM, affecting diverse cellular functions.
Purpose of the Study:
- To review LMNA mutations and splicing alterations in DCM.
- To discuss the interplay between LMNA and splicing regulators in DCM mechanisms.
Main Methods:
- Literature review of genetic mutations and splicing alterations in DCM.
- Analysis of studies employing mouse models for splicing factor function.
- Integration of next-generation sequencing findings.
Main Results:
- LMNA is the second most frequently mutated gene in DCM.
- Mutations in splicing factors, like RBM20, are implicated in DCM.
- Aberrant splicing and splice-site mutations are associated with DCM development.
Conclusions:
- LMNA mutations and splicing dysregulation are key in DCM.
- The interaction between LMNA and splicing regulators offers insights into DCM pathogenesis.
- Further research into these interactions may reveal novel therapeutic targets.
Abstract:
Mutations in the LMNA gene, which encodes for the nuclear lamina proteins lamins A and C, are responsible for a diverse group of diseases known as laminopathies. One type of laminopathy is Dilated Cardiomyopathy (DCM), a heart muscle disease characterized by dilation of the left ventricle and impaired systolic function, often leading to heart failure and sudden cardiac death. LMNA is the second most commonly mutated gene in DCM. In addition to LMNA, mutations in more than 60 genes have been associated with DCM. The DCM-associated genes encode a variety of proteins including transcription factors, cytoskeletal, Ca2+-regulating, ion-channel, desmosomal, sarcomeric, and nuclear-membrane proteins. Another important category among DCM-causing genes emerged upon the identification of DCM-causing mutations in RNA binding motif protein 20 (RBM20), an alternative splicing factor that is chiefly expressed in the heart. In addition to RBM20, several essential splicing factors were validated, by employing mouse knock out models, to be embryonically lethal due to aberrant cardiogenesis. Furthermore, heart-specific deletion of some of these splicing factors was found to result in aberrant splicing of their targets and DCM development. In addition to splicing alterations, advances in next generation sequencing highlighted the association between splice-site mutations in several genes and DCM. This review summarizes LMNA mutations and splicing alterations in DCM and discusses how the interaction between LMNA and splicing regulators could possibly explain DCM disease mechanisms.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
RNA Splicing
Mutation, Gene Flow, and Genetic Drift
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Mutations
Cardiomyopathy III: Hypertrophic Cardiomyopathy

